Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Adaptive designs for dual-agent phase I dose-escalation studies

Harrington, Jennifer A., Wheeler, Graham M., Sweeting, Michael J., Mander, Adrian P. and Jodrell, Duncan I. 2013. Adaptive designs for dual-agent phase I dose-escalation studies. Nature Reviews Clinical Oncology 10 (5) , pp. 277-288. 10.1038/nrclinonc.2013.35

Full text not available from this repository.


Anticancer agents used in combination are fundamental to successful cancer treatment, particularly in a curative setting. For dual-agent phase I trials, the goal is to identify drug doses and schedules for further clinical testing. However, current methods for establishing the recommended phase II dose for agents in combination can fail to fully explore drug interactions. With increasing numbers of anticancer drugs requiring testing, new adaptive model-based trial designs that improve on current practice have been proposed, although uptake has been minimal. We describe the methods available and discuss some of the opportunities and challenges faced in dual-agent phase I trials, as well as giving examples of trials in which adaptive designs have been implemented successfully. Improving the design and execution of phase I trials of drug combinations critically relies on collaboration between the statistical and clinical communities to facilitate the implementation of adaptive, model-based designs.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Nature Publishing Group
ISSN: 1759-4774
Last Modified: 07 Nov 2019 11:33

Citation Data

Cited 36 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item